US and EU regulatory authorities accept Plegridy(TM) (peginterferon beta-1a) marketing applications for review
Biogen Idec announced that U.S. and EU regulatory authorities have accepted the marketing applications for the review of Plegridy(TM) (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) has accepted Biogen Idec's Biologics License Application (BLA) for marketing approval of PLEGRIDY in the United States and granted the company a standard review timeline. The Marketing Authorisation Application (MAA) of Plegridy for review in the European Union was also validated by the European Medicines Agency...... Read More - http://www.ms-uk.org/index.cfm/PEGylatedinterferonbeta
Plegridy(TM) marketing applications accepted for review
Plegridy(TM) marketing applications accepted for review
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1939 Views
-
Last post by frodo
-
- 0 Replies
- 1305 Views
-
Last post by NHE
-
- 0 Replies
- 1695 Views
-
Last post by frodo
-
- 0 Replies
- 1245 Views
-
Last post by frodo
-
- 0 Replies
- 2098 Views
-
Last post by NHE
-
- 1 Replies
- 1785 Views
-
Last post by frodo
-
- 0 Replies
- 2491 Views
-
Last post by NHE
-
- 0 Replies
- 1073 Views
-
Last post by frodo
-
- 1 Replies
- 1506 Views
-
Last post by NHE